Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Clinical analysis of eculizumab in the treatment of atypical hemolytic uremic syndrome in children].

Zhonghua er ke za zhi = Chinese journal of pediatrics - 2 May 2026

Zhang Y X, Liu P, Liu Y J, Li Y L, Cao G H, Tian M, Liu C H

Abstract excerpt

Objective: To evaluate the efficacy and safety of eculizumab, a terminal complement inhibitor, in the treatment of pediatric atypical hemolytic uremic syndrome (aHUS), and explore strategies for treatment discontinuation. Methods: This was a case series study. Clinical data of the 10 children diagnosed with aHUS who were hospitalized and treated with eculizumab at Children's Hospital affiliated to Zhengzhou...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atypical Hemolytic Uremic Syndrome
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood Proteins

Share to Complement C3

Share to Complement C3b Inactivator Proteins

Share to Complement Factor H

Share to Prognosis

Share to Treatment Outcome

Source

Identifiers

PMID: 41986268
DOI: 10.3760/cma.j.cn112140-20251117-01035

Genes

C3
CFH
CFHR1
CFHR3
DGKE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Clinical analysis of eculizumab in the treatment of atypical hemolytic uremic syndrome in children].PMID 41986268Read ↗

Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.Semantic proximity Read ↗

Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.Semantic proximity Read ↗

Improved Renal Recovery with Eculizumab Therapy among Children with High Prevalence of Mutation-Associated Atypical Hemolytic Uremic Syndrome: A Retrospective Cohort Study.Semantic proximity Read ↗

Treatment discontinuation in atypical hemolytic uremic syndrome (aHUS): A qualitative study of international experts’ perspectives with associated cost-consequence analysisSemantic proximity Read ↗

Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic SyndromeSemantic proximity Read ↗

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.Semantic proximity Read ↗

New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.Semantic proximity Read ↗

Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients.Semantic proximity Read ↗

Atypical Hemolytic Uremic Syndrome in Children Aged <2 Years.Semantic proximity Read ↗

Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy.Semantic proximity Read ↗

Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.Semantic proximity Read ↗

Pediatric Atypical Hemolytic Uremic Syndrome Advances.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.